B ERLIN -- After multiple failed attempts, an immune checkpoint inhibitor has broken through and landed a significant overall ...

A label expansion for Keytruda in platinum-resistant ovarian cancer would further entrench MSD’s dominance in the PD-1 space.

Without an easy way to screen and with nondescript symptoms, ovarian cancer is often caught in late stages, requiring massive ...

Daiichi and Merck saw the highest ORR—57.1%—in patients who received the top dose of R-DXd. Yet the drugmakers have opted to ...

R-DXd showed a 50.5% objective response rate in platinum-resistant ovarian cancer, with a 5.6 mg/kg dose deemed optimal for further study. The safety profile was manageable, with 93.5% experiencing ...

Merck’s efforts to make headway in a cancer type that was an elusive target for its superstar oncology med Keytruda prove to ...

The DUO-O trial showed significant improvement in progression-free survival with Imfinzi, Avastin, and Lynparza, but no ...

Emily Pwee, 54, developed a fever and cough on Oct. 10, her husband, 54-year-old Jimmy Teo, told Shin Min Daily News . Teo, a ...

Investor event to provide update on pivotal Phase 3 study of IMNN-001 to be held in New York City on November 10, 2025Program will feature ...

Wrapped in Love’s brands feature everything from soft head covers and mastectomy camisoles to cozy socks with cool sayings.

Merck (MRK) stock is in focus as its blockbuster drug Keytruda as part of a combo regimen hits a secondary goal in a Phase 3 ...